NLRP3 and left ventricular hypertrophy: Pirfenidone improved TAC-induced left ventricular hypertrophy and myocardial fibrosis in a mouse model through inhibiting NLRP3 inflammasome assembly, and regulating the NLRP3-IL-1β signaling pathway in both the ROS-dependent and ROS-independent pathways (95).